CSL Behring

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: -

Website: http://www.cslbehring.com/

Clinical Trials

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Phase 3

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: Higher-volume C1-esterase inhibitor
Biological: Low-volume C1-esterase inhibitor
Biological: Higher-volume placebo
Biological: Low-volume placebo

First Posted Date: 2013-07-31

Last Posted Date: 2021-01-29

Lead Sponsor: CSL Behring

Target Recruit Count: 90

Registration Number: NCT01912456

Locations: 🇬🇧
Study Site, London, United Kingdom

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Phase 1

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: Berinert
Biological: CSL830

First Posted Date: 2013-01-04

Last Posted Date: 2013-04-05

Lead Sponsor: CSL Behring

Target Recruit Count: 16

Registration Number: NCT01760343

Locations: 🇩🇪
Study Site, Berlin, Germany

A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B

Phase 3

Completed

Conditions: Hemophilia B

Interventions: Biological: rIX-FP

First Posted Date: 2012-08-10

Last Posted Date: 2016-05-09

Lead Sponsor: CSL Behring

Target Recruit Count: 27

Registration Number: NCT01662531

Locations: 🇨🇦
McMaster Children's Hospital, Hamilton, Ontario, Canada
🇨🇿
Fakultni nemocnice Motole, Praha 5, Czech Republic
🇦🇺
The Royal Children's Hospital, Melbourne, Parkville, Victoria, Australia

and more 14 locations

A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route

Phase 1

Completed

Conditions: Hereditary Angioedema Types I and II

Interventions: Biological: C1-esterase inhibitor - single intravenous dose
Biological: C1-esterase inhibitor - subcutaneous medium dose
Biological: C1-esterase inhibitor - subcutaneous low dose
Biological: C1-esterase inhibitor - subcutaneous high dose

First Posted Date: 2012-04-12

Last Posted Date: 2021-02-01

Lead Sponsor: CSL Behring

Target Recruit Count: 18

Registration Number: NCT01576523

Locations: 🇩🇪
Study Site, Mainz, Germany

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Phase 3

Completed

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Polyradiculoneuropathy

Interventions: Biological: IgPro10
Biological: IgPro20 (low dose)
Biological: Placebo
Biological: IgPro20 (high dose)

First Posted Date: 2012-03-06

Last Posted Date: 2018-07-05

Lead Sponsor: CSL Behring

Target Recruit Count: 208

Registration Number: NCT01545076

Locations: 🇨🇦
Site Reference 1240048, Vancouver, British Columbia, Canada
🇩🇪
Site reference 2760053, Göttingen, Germany
🇨🇦
Site reference 1240007, Quebec, Canada

and more 88 locations

Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease

Phase 2

Terminated

Conditions: Crohn's Disease

Interventions: Biological: Placebo matching with BMS-945429
Biological: BMS-945429

First Posted Date: 2012-03-06

Last Posted Date: 2021-12-03

Lead Sponsor: CSL Behring

Target Recruit Count: 72

Registration Number: NCT01545050

Locations: 🇺🇸
Options Health Research, Llc, Tulsa, Oklahoma, United States
🇺🇸
Precision Research Institute, Llc, San Diego, California, United States
🇺🇸
University Of California, San Diego, La Jolla, California, United States

and more 6 locations

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Biological: rVIIa-FP
Biological: Placebo (0.9% normal saline)

First Posted Date: 2012-03-02

Last Posted Date: 2017-04-21

Lead Sponsor: CSL Behring

Target Recruit Count: 40

Registration Number: NCT01542619

Locations: 🇩🇪
Phase I Unit, Berlin, Germany

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)

Phase 1

Terminated

Conditions: Acute GvHD

Interventions: Biological: ALD518

First Posted Date: 2012-02-09

Last Posted Date: 2021-02-17

Lead Sponsor: CSL Behring

Target Recruit Count: 3

Registration Number: NCT01530256

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸
Loyola Medical Center, Maywood, Illinois, United States

and more 2 locations

A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

Phase 2

Completed

Conditions: Hemophilia B

Interventions: Biological: rIX-FP

First Posted Date: 2011-12-21

Last Posted Date: 2016-05-09

Lead Sponsor: CSL Behring

Target Recruit Count: 63

Registration Number: NCT01496274

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Indiana Hemophilia and Thrombosis Center, Inc., Indianapolis, Indiana, United States

and more 27 locations

Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy

Phase 2

Completed

Conditions: Arthritis, Psoriatic

Interventions: Biological: Placebo matching BMS-945429
Biological: BMS-945429

First Posted Date: 2011-12-13

Last Posted Date: 2021-11-05

Lead Sponsor: CSL Behring

Target Recruit Count: 165

Registration Number: NCT01490450

Locations: 🇪🇸
Local Institution, Sevilla, Spain
🇨🇦
Centre De Rhumatologie De L Est Du Quebec, Rimouski, Quebec, Canada
🇺🇸
Sarasota Arthritis Research Center, Sarasota, Florida, United States

and more 9 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy